{"id":"abciximab-bolus-only-regimen","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Bleeding"},{"rate":"1-2","effect":"Thrombocytopenia"},{"rate":"2-5","effect":"Hypotension"},{"rate":"1-3","effect":"Bradycardia"},{"rate":"2-4","effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abciximab irreversibly binds to the glycoprotein IIb/IIIa integrin receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, it prevents fibrinogen-mediated platelet cross-linking and clot formation. The bolus-only regimen delivers a single intravenous dose without subsequent infusion, providing rapid antiplatelet effects for acute coronary intervention.","oneSentence":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:41:59.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome undergoing percutaneous coronary intervention"},{"name":"Prevention of ischemic complications in high-risk patients undergoing coronary angioplasty"}]},"trialDetails":[{"nctId":"NCT00229515","phase":"PHASE4","title":"Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI","status":"UNKNOWN","sponsor":"Marco Valgimigli","startDate":"2004-11","conditions":"Myocardial Infarction","enrollment":744},{"nctId":"NCT00929279","phase":"PHASE4","title":"Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2008-11","conditions":"Acute Coronary Syndrome","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"abciximab bolus only regimen","genericName":"abciximab bolus only regimen","companyName":"Università degli Studi di Ferrara","companyId":"universit-degli-studi-di-ferrara","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abciximab is a chimeric monoclonal antibody that blocks the glycoprotein IIb/IIIa receptor on platelet surfaces, preventing platelet aggregation and thrombus formation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of ischemic complications in high-risk patients undergoing coronary angioplasty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}